AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Acquisition 8 Sep - Park Medicity Prayagraj Limited incorporated on Sept 8, 2026 for 550-bed hospital in Prayagraj, Rs.0.15 crore.
Source: Bse
Park Medi World Limited (PARKHOSPS)
Micro CapPharma stocks · Micro cap · NSE
Park Medi World Limited operates a network of 16 multi-super specialty hospitals across 14 cities in 5 states, primarily in North India. It focuses on providing affordable, high-quality healthcare through a cluster-based approach, with 3,960 beds including 1,040 ICU beds, and a comprehensive range of specialty services.
Data qualityFresh enough for analysisQuote updated 21 Oct, 03:31 pm ISTDetails
Quote21 Oct, 03:31 pm IST
Base fundamentals14 Oct 2026 · screener
Latest result08 Sept, 03:27 pm IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage14/14 · 100%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
60BullishSMA20 -7.4% / mo · RSI oversold · MACD − · sector +4.9pp vs Nifty 500 (3M)
Stock trend: 34
Sector RS: 100
Sector 3M: -0.7% vs Nifty 500 -5.6%
Pharma FPI tailwindNot confirmed
Latest mapped FPI equity flow was not positive. View sector evidence
Technical chart
PARKHOSPSD candles · FIT view-6.1%Latest close ₹222.40 on 2026-10-21
Daily history is available from 2025-12-17; the requested 1Y window is partially covered.
Bar
-2.0%
RSI
25
MACD hist
-4.57
52W pos
51%
2026-10-21O ₹226.90H ₹229.50L ₹220.70C ₹222.40Vol 5.5L sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
PARKHOSPSNifty PharmaNifty 500
- PARKHOSPS
- -17.8%
- Nifty 500
- -6.5%
- Nifty Pharma
- -2.0%
- Vs Nifty 500
- -11.3 pp
Chart stats
21 Oct 2026- From 52W high
- -27.1%
- 52W range position
- 51%
- ATR (14)
- 5.0%
- Volume vs 20D
- 0.55x
- Avg traded value
- ₹25.4 Cr
- 20D price channel
- ₹220.7 - ₹291.5
₹305
₹138.1 - ₹305
₹11.1
Latest completed session
20-session average
45.5% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is mixed.
Suggested next step
Research, do not rush
The evidence is not strongly aligned. Compare peers and wait for a cleaner setup.
U-Score
Legacy · WATCHLIST44
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Good57
Revenue +19.3% · PAT +34.9% YoY
Technical
Bullish60
Price trend and sector-relative-strength timing.
Valuation
Legacy model+23.7%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence74
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Good · 57/100Rev +19% YoY · PAT +35% YoY · operating leverage · margin compression
Filed 08 Sept 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹476 Cr | +19.3% | +3.5% |
| EBITDA | ₹126 Cr | +20.0% | -0.8% |
| Operating margin | 26.0% | +0 bps | -200 bps |
| PAT | ₹89 Cr | +34.9% | +15.6% |
| PAT margin | 18.7% | +216 bps | +196 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 37.20
- P/B
- 5.13
- EV/EBITDA
- 20.09
- Market Cap
- 10345.00Cr
Profitability
- ROE
- 16.80%
- ROCE
- 19.50%
- ROA
- 10.62%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 17.00%
- EPS 5Y
- 11.00%
- Revenue 3Y
- 10.00%
- EPS 3Y
- 5.00%
Balance Sheet
- Debt/Equity
- 0.34
- Interest Coverage
- 8.79×
- Altman Z
- 5.38
- Book Value
- 46.80
Cash Flow
- FCF Yield
- 0.13%
- FCF Positive Y
- 3/5
- OCF
- 329.00 Cr
- EPS TTM
- 6.63
Shareholding
- Promoter Hold
- 82.89%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 61%
Financial History
Updated 21/10/2026
Revenue
₹ CrLatest: 476+3.5% vs prev
Net Profit
₹ CrLatest: 89.0+15.6% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Bearish setupTrend is weak — long-term trend down. RSI 25.
- Price below SMA200 (long-term downtrend) — short-term bounces likely countertrend.
- SMA20 falling (~8.0% over last month) — short-term momentum negative.
- RSI(14) at 25 — oversold zone; bounce conditions.
- MACD below signal, histogram expanding negatively — bearish momentum building.
- 27% off 52W high · 61% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
53
RS percentile
Stage 1 Base / Transition
1M return
-21.9%
3M return
-17.8%
6M return
-2.8%
1Y return
-
RS 1D
+3
RS 20D
-23
Sector rank
#1
Industry rank
#14
Stage evidence
- Price is 15.2% below the 30-week proxy without full trend alignment.
- The 30-week proxy changed +3.5% over 20 sessions.
- The moving-average structure does not confirm Stage 2 or Stage 4.
50-DMA
price below
200-DMA
price below
Sector
leading
Industry
leading
Partial-history RS: the 3M and 6M weights are re-normalised because 12M history is unavailable.
Relative-strength line vs Nifty 500 (base 100)
208 observations
21 Oct 2026Value 161.73-1.49%
RS vs Nifty 500162
Valuation & peers
U-Score 44 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
Valuation & peers
U-Score 44 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
WATCHLIST
Fundamental score breakdown
U band · WATCHLISTValuation5/30
Growth10/25
Quality11/20
Balance Sheet10/15
Cash Flow3/10
Piotroski
8/9 (+5)
Penalties
0
Raw sum
44
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
44/100 · legacy band WATCHLIST
Positive drivers
- Piotroski is strong at 8/9.
- Fair-value margin of safety is positive at 23.7%.
- Balance sheet contributes 10/15 to the score.
Main drags
- Valuation is weaker at 5/30; verify the latest quarterly trend.
- Cash flow is weaker at 3/10; verify the latest quarterly trend.
- Growth is weaker at 10/25; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
37.2
PB
5.1
EV/EBITDA
20.1
ROE
16.8%
ROCE
19.5%
FCF Yield
0.1%
Debt/Equity
0.3
MoS
+23.7%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
44
Previous: 44
Legacy U-Score band
WATCHLIST
Previous: WATCHLIST
Margin of safety
+23.7%
Previous: +21.9%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
41
41
43
44
44
44
44
44
44
44
44
44
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹83.55
-166.2% MoS
Growth-justified P/E
44.0
Growth-justified Value
₹291.59
+23.7% MoS
PEG
4.33
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
JLHL
Micro
Jupiter Life Line Hospitals Limited
Healthcare Services
match 166
43
41.7
13.1%
+5%
WATCHLIST
HCG
Micro
Healthcare Global Enterprises Limited
Healthcare Services
match 165
28
182.0
2.5%
-727%
OVERVALUED
AGARWALEYE
Micro
Dr. Agarwal's Health Care Limited
Healthcare Services
match 163
30
99.3
6.0%
-122%
OVERVALUED
ARTEMISMED
Small
Artemis Medicare Services Limited
Healthcare Services
match 157
39
44.2
12.0%
+10%
WATCHLIST
DRAGARWQ
Small
Dr Agarwals Eye Hospital Limited
Healthcare Services
match 153
61
32.7
24.2%
+28%
UNDERVALUED
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Where growth can come from, and what can break the case
Thesis intactReviewed 2026-06-03T11:41:39.433Z
Management commentary snapshot
Park Medi World reported its 'finest year' in FY'26 with record financial and operating performance. Revenue grew 21% YoY to INR 16,794 Mn, EBITDA rose 20% YoY to INR 4,443 Mn (margin 26.5%), and Net Profit increased 27% YoY to INR 2,736 Mn (margin 16.3%). Bed capacity expanded 20% YoY to 3,610 beds.
The company delivered record financial and operating performance in FY'26, driven by capacity additions and improved utilization. Management's focus on disciplined capital allocation, balance sheet strength, and measured expansion, alongside a clear roadmap for significant bed capacity expansion, supports the ongoing growth thesis.
Current business mix
Speciality Wise Revenue Bifurcation (FY'26)
Latest issuer-disclosed distribution across 9 reported categories.
Internal Medicine29.5%
Cardiology14.8%
General Surgery10.4%
Orthopaedics8.1%
Oncology10.8%
Gastroenterology5.8%
Urology6.3%
Neurology6.4%
Others7.9%
Growth engines
Network Expansion
Bed capacity is projected to grow by over 50% between FY'26-28, reaching 5,460 beds. Brownfield expansion aims to improve asset utilization and add beds at lower cost.
Inorganic Growth
Focus on North India clusters and adjacent markets, leveraging a strong track record of turnaround and integration to capitalize on fragmented market opportunities.
Asset-Light & Capital-Efficient Growth
Expansion through O&M contracts and partnerships enables faster ramp-up with lower upfront capital intensity, supporting ROCE-accretive growth.
Operational & Clinical Excellence
Investments in advanced medical equipment and robotics, expansion of super-specialties, and complex procedures are improving ARPOB and overall efficiency.
Capacity and execution
KP Institute of Medical Sciences, Agra
Acquired and commissioned in Feb 2026, adding 360 beds. This was the largest acquisition to date.
Krishna Super Speciality Hospital, Bhatinda
Acquired and commissioned in Jul 2025, adding 250 beds.
Park Hospital, Panchkula
Construction completed for this 350-bed greenfield project, commissioned on Apr 10, 2026.
Febris Hospital, Narela – Delhi
Acquired 200 beds, expected to be commissioned in Q2 FY'27.
Tailwinds
Government & Policy Push
Ayushman Bharat (40+ Cr cards, 9+ Cr hospitalizations) and CGHS rate revisions (~10-15% increase) are driving demand and improving access.
Rising Insurance Penetration
Health insurance penetration is expected to increase from 40-42% (FY'24) to 45-50% (FY'26E), improving healthcare accessibility and hospitalization rates.
Increasing Health Awareness
Improving awareness for preventive and curative care due to urbanization, coupled with rising disposable income, is accelerating healthcare demand.
Medical Tourism
India remains a preferred destination for medical tourists due to cost competitiveness and quality care, with recovery visible post-COVID.
Management accountability
What management said, and what results must prove
Issuer guidance and extracted claims are tracked against later reported outcomes. Treat these as management statements, not IndiaPulse forecasts.
Analyst reading lens
Compare BOTH
The presentation provides both Q4 YoY and full-year (FY) YoY comparisons, which are crucial for assessing both recent momentum and overall annual performance in the healthcare sector. QoQ is also available for Q4 vs Q3, indicating sequential trends.
Sector KPIs management disclosed
Revenue (FY'26)
Revenue (ex Other income) increased 21% YoY to INR 16,794 Mn in FY'26. Q4 FY'26 revenue grew 30% YoY to INR 4,604 Mn.
EBITDA (FY'26)
EBITDA grew 20% YoY to INR 4,443 Mn in FY'26, with a margin of 26.5%. Q4 FY'26 EBITDA increased 44% YoY to INR 1,274 Mn, with a margin of 27.7%.
Net Profit (FY'26)
Net Profit increased 27% YoY to INR 2,736 Mn in FY'26, with a margin of 16.3%. Q4 FY'26 Net Profit grew 47% YoY to INR 768 Mn, with a margin of 16.7%.
Bed Capacity (FY'26)
Bed capacity increased 20% YoY to 3,610 beds in FY'26. As of May 2026, total bed capacity is 3,960.
Management forward view
FY'26 Performance
MD Dr. Ankit Gupta stated FY'26 was the 'finest year' with record financial and operating performance, largest-ever capacity addition, and strengthened balance sheet.
Post-IPO Priorities
Immediate priorities include seamless integration of acquired assets, improving utilization across newer facilities, and sustaining profitability through internal accruals.
Medium-Term Strategy
Management will continue to selectively pursue growth opportunities while maintaining commitment to affordable, high-quality healthcare and long-term value creation.
Thesis monitor
Numbers and claims to verify in the next filings
| Checkpoint | Current evidence | What to verify next |
|---|---|---|
| Bed Capacity | 3,960 beds (as of May 2026) | Progress towards 5,460 beds by FY'28, especially commissioning of Narela (Q2 FY'27), Gorakhpur (Apr'27), Kanpur (Dec'26), Mohali (Sep'27), Ambala (Oct'27), and Rohtak (Jan'28). |
| Occupancy % | 64.1% (FY'26) | Ramp-up of utilization across newer facilities and recently commissioned hospitals like Panchkula and Agra to drive revenue and profitability. |
| Net Debt | Negative Net Debt (INR 3,230 Mn) (FY'26) | Maintenance of strong balance sheet and disciplined capital allocation, ensuring internal accruals fund growth and leverage remains comfortable amidst expansion. |
| EBITDA Margin | 26.5% (FY'26) | Sustaining profitability and margins as new capacities are integrated and ramped up, especially given the significant expansion plans. |
Verification checkpoints are IndiaPulse research interpretation, not investment advice.
Trust Score
74Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 75th percentile of the scored universe and 65th percentile within Pharma. No major sub-score weakness stands out.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
16 docs text-extracted · 4 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
75th percentile
overall median 67 · Pharma: 65th pctile, median 70 · Micro: 56th pctile, median 73
Evidence depth
Financial-only
16 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
65
acceptable · profit to cash conversion
Balance sheet
89
strong · leverage and solvency
Discipline
60
acceptable · capital discipline
Results
71
acceptable · quarterly consistency
Trust positives
- ▸Promoter holding is 82.9%.
- ▸Promoter pledge is zero.
- ▸FCF yield is positive at 0.1%.
- ▸Latest 3 quarters had positive YoY PAT growth.
Trust risks
- ▸No major Trust Lite risk flags.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Park Medi World Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Announcement
Announcement under Regulation 30 (LODR)-Press Release / Media Release 22 Sep - Park Group won three honours at Healthcare Pioneers of Delhi 2026; capacity expected to reach 6,600 beds.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 16 Sep - Management will skip Anand Rathi G-200 Summit 2026 on Sept 21; other conference plans unchanged.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 5 Sep
Source: Bse
Concall transcriptAug 2026
Aug 2026 · Transcript
Source: Bse
Investor presentationAug 2026
Aug 2026 · PPT
Source: Bse
AnnouncementAug 2026
Aug 2026 · Announcement under Regulation 30 (LODR)-Acquisition 31 Aug - Board approved wholly owned SPV for 550-bed Prayagraj hospital PPP project on August 31, 2026.
Source: Bse
AnnouncementAug 2026
Aug 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 18 Aug - Management to participate in Divitiae Investments virtual investor session on August 22, 2026.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 5 Aug
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 5 Aug - Management to meet investors at three conferences on August 12, 13 and 25, 2026 in Mumbai.
Source: Bse
AnnouncementJul 2026
Jul 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 3 Jul - Park Medi World will hold an in-person analyst/investor group meeting in Gurugram on July 8, 2026.
Source: Bse
AnnouncementJun 2026
Jun 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 8 Jun - Park Medi World to participate in InsightX 2026 virtual investor conference on June 12, 2026.
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.